Email Updates

You are here

Pre-Exposure Prophylaxis 2.0: New Drugs and Technologies in the Pipeline

Include in
Published Research

New PrEP agents in clinical development include novel oral agents (eg, tenofovir alafenamide and islatravir [also known as MK-8591]), long-acting injectables (eg, cabotegravir), vaginal rings, broadly neutralising monoclonal antibodies, topical products (including gels, films, and enemas), and multipurpose technologies. In addition, new drug delivery systems, such as implants and transdermal devices, are promising strategies that are being developed for HIV prevention.

September 23, 2019
Lancet HIV